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Conclusions: For a moving target, it was confirmed that the 4D CBCT 
based registration provided more accuracy compared to 3D CBCT 
based registration. 
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Purpose/Objective: Irradiation of pancreatic tumors requires large 
margins to account for respiratory-induced intrafractional tumor 
motion. These margins are derived from a single pre-treatment 4DCT 
scan. This respiratory-induced intrafractional motion can be visualized 
using implanted fiducial markers. 
The purpose of the current study is to quantify the respiratory-
induced motion of pancreatic cancer, both on the 4DCT scan as well 
as on daily cone beam CT (CBCT) scans during a 5 week course of 
radiation to reveal possible trends during the course of treatment. 
Materials and Methods: Eight patients (4 male / 4 female) with 
borderline resectable pancreatic cancer were treated with 25 x 2Gy 
plus weekly gemcitabine 300 mg/m2. All patients received 2 to 4 
fiducial markers by endoscopic ultrasound-guided implantation. The 
amplitude of respiratory-induced motion was measured on the pre-
treatment 4DCT scan and also on all available daily CBCT scans. Phase 
reconstructions of the CBCT scans were made by an automated 
selection of the 2D projection images corresponding to the peak 
inhale and exhale phases. These reconstructions were matched to the 
(reference) planning CT. The amplitudes (differences between the 2 
extreme positions) were analyzed by matching on the markers (in 
three directions) and on the diaphragm (superior-inferior (SI) direction 
only). Rotations and deformations of the tissue were not analyzed. 
The amplitudes were linearly fit as a function of time (i.e. treatment 
day). The fits were tested for significance using a Student’s t-test and 
statistical significance was assumed at p≤0.05. 
Results: The amplitude of intrafractional motion of the markers was 
greatest in the SI direction (mean 5.9mm, SD: 2.7mm on CBCT). 
Differences up to 5.1mm (range: 0.3 - 5.1 mm) were found between 
the amplitude on the 4DCT scan and the mean amplitude of all CBCT 
scans of a single patient.  
The analysis of daily respiratory-induced motion of the markers 
revealed significant trends in the amplitude as a function of time 
(table and figure). The diaphragm did not always show the same trend 
as the markers. For the markers neither the amplitudes nor the trends 
were significant in the other 2 directions (data not shown). 
Conclusions: The 4DCT used for treatment planning is often not 
representative of the respiratory-induced motion amplitude during 
treatment. The CBCT projection images showed significant time 
trends in the amplitude of respiratory-induced motion during a five 
week course of radiation. These time trends in the amplitudes 





PD-0045   
Time-resolved dose reconstruction of VMAT delivery to moving 
targets with and without dynamic MLC tracking 
T. Ravkilde1, P.J. Keall2, C. Grau1, M. Høyer1, P.R. Poulsen1 
1Aarhus University Hospital, Department of Oncology, Aarhus, 
Denmark  
2University of Sydney, Sydney Medical School, Sydney, Australia  
 
Purpose/Objective: Dynamic multi-leaf collimator (DMLC) tracking 
can mitigate the dosimetric impact of target motion during volumetric 
modulated arc therapy (VMAT). However, residual dosimetric errors 
still exist. The purpose of this study was to create a simple model for 
time-resolved reconstruction of the delivered dose distribution and to 
validate its ability to predict the time-resolved dosimetric errors 
measured during VMAT of moving targets with and without DMLC 
tracking. 
Materials and Methods: DMLC tracking experiments were performed 
on a Trilogy linear accelerator (Varian Medical Systems) connected to 
prototype DMLC tracking software. A three-axis motion stage, carrying 
a Delta4 phantom (Scandidos) on a custom built platform, reproduced 
eight representative tumor trajectories; four lung and four prostate. 
For each trajectory, two VMAT treatment plans (low and high 
modulation) were delivered with and without DMLC tracking. During 
tracking the MLC leaves were continuously refitted to the 3D target 
position measured by an electromagnetic RayPilot transponder 
(Micropos Medical) at 30 Hz. Doses were measured with the orthogonal 
detector arrays of the Delta4 phantom at a rate of 72 Hz.  
Offline, the measured doses were down-sampled to steps of 10 dose 
pulses to reduce noise (mean time resolution of 20 Hz). The time-
resolved dose distribution was compared to a reference dose 
measured without target motion by use of time-resolved 3%/3mm γ-
tests with exclusion of detectors receiving less than 5% of the 
maximum dose in the accumulated reference dose. For all 
experiments, the time-resolved dose delivered to each detector in the 
phantom was calculated by a simple model that included the target 
position, the MLC aperture convolved with a 2D dose kernel, the dose 
rate, and a percentage depth dose. Like for the measurements, the 
time-resolved 3%/3mm γ-test was also performed for the 
reconstructed doses by comparison with the reconstructed dose to a 
static phantom. Finally, the reconstructed and the measured γ failure 
rates were compared for each experiment. 
Results: 
 
Fig. A compares the measured and reconstructed transient and 
cumulative doses for a single detector during beam delivery in one 
experiment. The scatter plots in Fig. B compare the measured and 
